Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion
Key takeaways
- As per the deal, Merck will pay $73 for each of Bio-Techne's US-listed shares, representing a 36% premium to the company's one-month volume weighted average trading price.
- Bio-Techne, which is headquartered in the US but has a significant global presence, develops and manufactures life science reagents, analytical instruments, and clinical diagnostics.
- Bio‑Techne operates in 34 locations worldwide and employs approximately 3,100 people.
Merck KGa A to buy Bio-Techne for $11.3bn in life science footprint expansion Merck KGa A to buy Bio-Techne for $11.3bn in life science footprint expansion · Medical Device Network Robert Barrie Thu, June 25, 2026 at 9:22 PM GMT+7 3 min read TECH MRK MRK.DE Merck KGa A has agreed to acquire life sciences company Bio-Techne Corporation for $11.3bn, representing one of the largest financial outlays by a drugmaker so far this year.
As per the deal, Merck will pay $73 for each of Bio-Techne's US-listed shares, representing a 36% premium to the company's one-month volume weighted average trading price. The offer is a 25% premium to Bio-Techne's last market close of $58.88 on 24 June.
Bio-Techne, which is headquartered in the US but has a significant global presence, develops and manufactures life science reagents, analytical instruments, and clinical diagnostics. The company also supplies proteins, antibodies, and small molecules used in drug development.